The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma.

We have determined the effect of prior inhalation of the LTD4 antagonist SK&F 104353 on the response to aspirin ingestion in six aspirin-sensitive asthmatic subjects (five women and one man 31 to 54 yr of age) in a randomized, double-blind, cross-over, placebo-controlled study. Pretreatment with inhaled SK&F 104353 (average nebulized dose, 893 micrograms) inhibited the response by a mean of 47% (p = 0.02). The inhibition was partial, ranging from 43 to 74% in five subjects. In the remaining subject, there was no effect of the drug on the asthmatic response. We conclude that the mechanism of aspirin-induced asthma is at least partially mediated by the leukotrienes in the majority of susceptible patients and that leukotriene antagonists may be useful in the treatment of aspirin-induced asthma.
AuthorsP E Christie, C M Smith, T H Lee
JournalThe American review of respiratory disease (Am Rev Respir Dis) Vol. 144 Issue 4 Pg. 957-8 (Oct 1991) ISSN: 0003-0805 [Print] UNITED STATES
PMID1928974 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Dicarboxylic Acids
  • SRS-A
  • Aspirin
  • pobilukast
  • Adult
  • Aspirin (adverse effects)
  • Asthma (chemically induced, drug therapy, physiopathology)
  • Dicarboxylic Acids (therapeutic use)
  • Drug Evaluation
  • Female
  • Forced Expiratory Volume (drug effects)
  • Humans
  • Male
  • Middle Aged
  • SRS-A (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: